Abatacept in Individuals Who aRe Considered At Risk of Developing Inflammatory Arthritis (ARCADIA)
Phase II Proof of Concept Study of Abatacept (Orencia) in Individuals Who aRe Considered At Risk of Developing Inflammatory Arthritis
Sponsor: University of Leeds
Terminated
The CI terminated ARCADIA early due to a number of reasons. These include the difficulty in recruiting and being placed on pause during the COVID pandemic, plus limited staffing at that time \& the need to considerably amend the eCRF MACRO system
Other terminated trials from University of Leeds
This PHASE2 trial investigates Inflammatory Arthritis and is currently terminated or withdrawn. University of Leeds leads this study, which shows 7 recorded versions since 2020 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Apr 2025 — Present [monthly]
Terminated PHASE2
Status: Unknown → Terminated
-
Sep 2024 — Apr 2025 [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
May 2024 — Jul 2024 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jan 2021 — May 2024 [monthly]
Recruiting PHASE2
▶ Show 2 earlier versions
-
Apr 2020 — Jan 2021 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Mar 2020 — Apr 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Feb 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University of Leeds
For direct contact, visit the study record on ClinicalTrials.gov .